Application of transferrin combined GV-971 capsule and composition containing GV-971 capsules

A technology of transferrin and mannatide sodium, applied in the directions of transferrin, drug combination, peptide/protein components, etc., can solve the problem of unclear mechanism of action of AD model

Active Publication Date: 2020-08-11
江苏豪思睦可生物科技有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The mechanism of action in AD models is still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of transferrin combined GV-971 capsule and composition containing GV-971 capsules
  • Application of transferrin combined GV-971 capsule and composition containing GV-971 capsules
  • Application of transferrin combined GV-971 capsule and composition containing GV-971 capsules

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0040] The preparation method of described transferrin is as follows:

[0041] The following steps are sequentially included: preparation of pretreatment liquid, purification by hydrophobic chromatography, concentration and replacement.

[0042] Step 1. Preparation of pretreatment solution: the purpose of this step is to redissolve the protein in the precipitated human plasma CohnIV fraction, remove the filter aid, and remove some miscellaneous proteins after reconstitution.

[0043] Sub-step 1, the first reconstitution treatment: dissolve the solid CohnIV component into PBS buffer, mix well, and obtain the first reconstitution solution.

[0044] The mass volume ratio (w / v) of the above-mentioned human plasma CohnIV component to the PBS buffer is 1: (2-10), preferably 1:3.5; the above-mentioned PBS buffer is: 10-50mmol / LPBS, pH6.0- 8.0, preferably 20 mmol / LPBS, pH 7.5.

[0045] Sub-step 2, the first centrifugation treatment: centrifuge the above-mentioned first complex solutio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of a transferrin combined GV-971 capsule and a composition containing the GV-971 capsule. The invention also discloses an application of the transferrin combinedGV-971 capsule in preparation of drugs for preventing or/and improving or/and treating dementia or/and cognitive impairment. The composition containing the GV-971 capsules comprises the GV-971 capsules and transferring. The beneficial effects are as follows that the transferrin and the GV-971 capsules are combined for use, so that the effect of the GV-971 capsules on preventing, improving and treating Alzheimer's disease and other types of dementia such as vascular dementia, frontal temporal dementia, lewis body dementia and cognitive disorder caused by infection is further improved.

Description

technical field [0001] The invention belongs to the application field of biological medicines, and in particular relates to the combined use of transferrin and mannote sodium capsules to further improve the effect of mannote sodium capsules in treating Alzheimer's disease and other types of dementias. Background technique [0002] Mannate Sodium Capsules (GV-971, trade name "Nine Phase One") is a low-molecular-weight acidic oligosaccharide compound extracted from marine brown algae. The drug is my country's original and the world's first new drug for the treatment of Alzheimer's disease (AD) targeting the brain-gut axis. Previously, the world's treatment of AD mainly relied on five previously marketed drugs, all of which were mainly aimed at delaying the progression of mid-to-early symptoms of AD and improving the clinical symptoms of early-stage AD. The theory supporting the trials of new anti-AD drugs is that the deposition of β-amyloid in the brain triggers inflammation,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/40A61K31/702A61P25/28C07K14/79C07K1/20C07K1/30C07K1/36C07K1/14
CPCA61K38/40A61K31/702A61P25/28C07K14/79A61K2300/00
Inventor 栗琳谢蓝崔雅轩张丽丽潘媛媛肖冰心丁亮
Owner 江苏豪思睦可生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap